Brain Training Program Lumosity Improves Overall Cognition In Clinical Trial
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

In the BRIGHT-Mind randomized trial, 801 healthy adults trained at home for 12 weeks with Lumosity or watched educational videos. Among 677 participants in the primary analysis, the Lumosity group improved more on an independent battery of cognitive tests; the findings are scheduled for presentation at the CTAD conference on November 18, 2026. The trial does not show whether benefits last or apply to people with cognitive impairment.

Lumosity improved scores on a separate cognitive-test battery compared with an active control in a 12-week randomized trial of healthy adults, according to results from the BRIGHT-Mind study. The findings, involving 801 adults aged 25 to 80, are scheduled for presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston on November 18, 2026.

For listenersOffer from Amazon

Turn quiet afternoons into listening time

  • Thousands of audiobooks, podcasts and originals
  • Listen on your phone, tablet or Echo — also offline
  • Cancel anytime
Try Audible free Free trial for new members
As an affiliate, we earn on qualifying purchases.

Participants trained at home with Lumosity or used a comparison program of educational videos, which also provided a mentally engaging computer activity. Of the 801 enrolled, 677 were included in the primary analysis. They completed a separate 12-test cognitive battery rather than relying only on scores from games used during training. The Lumosity group improved more than the comparison group; the reported difference had a p-value of 0.00032.

The study report described the difference as roughly the size of the test-score gap between participants about 6.7 years apart in age. It also said the cognitive benefit was similar across the trial’s age range. This comparison gives a reference for the size of the score difference; it does not mean participants’ brains became 6.7 years younger.

Participants were asked to train for about 15 to 25 minutes a day, at least five days a week. Among those assigned to Lumosity, 83.6% completed at least 13 hours over the 12 weeks. No adverse events related to either program were reported, according to the study material.

At a glance
reportWhen: Results scheduled for presentation Nove…
The developmentResults from a randomized trial of Lumosity training in healthy adults are due to be presented at the 19th Clinical Trials on Alzheimer’s Disease Conference.

Reported Gains Beyond Game Scores

The trial’s primary outcome came from tests separate from the training games, assessing whether participants improved on measures beyond the activities they practiced. The comparison group also performed a mentally engaging activity rather than receiving no intervention, helping account for some effects of computer use and general engagement.

Participants also reported changes beyond test performance. On the Patient Global Impression of Improvement measure, 70% of Lumosity participants said their concentration, memory or ability to think clearly had improved, compared with 46% in the video group (p < 0.0001). On the Sheehan Disability Scale, the Lumosity group reported greater cognition-related improvement in work or school, social life and home responsibilities (p = 0.00080). These participant-reported results were exploratory and do not establish everyday benefit.

The trial does not establish that Lumosity prevents dementia, treats cognitive problems or produces lasting gains. Its findings concern performance during a short trial and do not demonstrate long-term protection from cognitive decline.

Products Worth Considering

Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale

Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47mm, Carbon Gray DLC Titanium with Black/Whitestone Band

Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Black

Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Black

As an affiliate, we earn on qualifying purchases.

How BRIGHT-Mind Tested Training

BRIGHT-Mind enrolled adults aged 25 to 80 who were described as healthy. Participants were randomly assigned to Lumosity or educational videos and trained at home over 12 weeks. The control activity was intended to be mentally engaging, providing a comparison with an active program rather than no intervention.

The research team also examined MRI scans from a subgroup. Across 220 evaluable participants, a prespecified analysis assessed brain-predicted age difference. In participants aged 60 to 80, that measure changed about 1.5 years more favorably in the Lumosity group than in the comparison group. Further analyses in older participants found less enlargement of the brain’s ventricles and greater preservation of cortical thickness in regions associated with attention and cognitive control. Those detailed regional analyses were exploratory, and MRI changes do not by themselves establish a clinical benefit.

The results are being reported by Lumos Labs, the company behind Lumosity. Bob Schafer, the company’s chief executive and the study’s corresponding author, said the trial was designed to test whether training improved performance beyond the games. The conference presentation is the next public reporting milestone identified in the source material.

“The results are encouraging evidence that training with Lumosity can improve performance on cognitive tests beyond the games themselves.”

— Bob Schafer, Lumos Labs CEO and BRIGHT-Mind corresponding author

Limits on What the Trial Shows

The trial lasted 12 weeks, so it cannot establish whether the reported cognitive-test differences persist after training stops or with continued use. The study enrolled healthy adults; its findings do not establish whether the same outcomes apply to people with cognitive impairment or neurological or psychiatric conditions.

The source material does not provide a full account of the trial’s methods, participant characteristics beyond age and health status, or the absolute cognitive-score changes and confidence intervals. The participant-reported outcomes were exploratory, as were the detailed analyses of ventricle volume and cortical thickness. The MRI brain-predicted age analysis was planned in advance, but its meaning for health or daily functioning remains uncertain.

The reported absence of program-related adverse events applies to this study and its duration; it does not establish safety for every user or over longer periods. The results are also being presented at a conference, and the material provided does not include a full published paper for independent review.

Conference Presentation and Longer Follow-Up

The study results are scheduled for presentation at the 19th CTAD Conference in Boston on November 18, 2026. Further reporting may provide details on the methods, the size and precision of the cognitive effects, and how the analyses were conducted.

Longer studies are needed to assess whether the gains continue with ongoing training, fade after participants stop, or are associated with changes in daily functioning. Research would also be needed before drawing conclusions about people with cognitive impairment or dementia prevention. The evidence described here concerns a 12-week trial in healthy adults and does not establish a long-term treatment effect.

Key Questions

What did the Lumosity trial find?

Among 677 participants in the primary analysis, those assigned to Lumosity improved more than the educational-video comparison group on a separate 12-test cognitive battery after 12 weeks.

Did the trial show that Lumosity prevents dementia?

No. The study involved healthy adults and measured outcomes over 12 weeks. The reported results do not establish dementia prevention or treatment.

Were the brain-scan findings definitive?

The brain-predicted age difference analysis was planned in advance, but the detailed findings on ventricles and cortical thickness were exploratory. Their clinical meaning and durability remain unclear.

When will the results be presented?

The BRIGHT-Mind results are scheduled for presentation at the CTAD Conference in Boston on November 18, 2026.

Source: news-medical.net

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

How to Choose Between a Humidifier and a Dehumidifier at Home

No matter your home’s moisture issues, learning how to choose between a humidifier and dehumidifier can improve comfort and health—keep reading to find out how.

Scientists may have finally found how Alzheimer’s kills brain cells

Researchers have identified a new mechanism explaining how Alzheimer’s disease kills brain cells, opening potential pathways for treatment.

Autism Rule

A new autism-related regulation has gained widespread attention, prompting discussions on its implications and future developments.

Bioengineered Chewing Gum May Offer A Way To Fight HPV And Other Microbes

Researchers develop bioengineered chewing gum designed to fight HPV and other microbes, offering a potential new method for infection prevention.